HIF, Hypoxia Research & Stem Cell News

PluristemBegins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease

Pluristem Therapeutics Inc. today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company`s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

Enrollment began at the Center for Therapeutic Angiogenesis in Birmingham, Ala., one of two clinical sites in the U.S. Duke University Medical Center will also be screening patients for the trial. The initiation of this study follows the approval of the Company`s Investigational New Drug (IND) application to begin clinical trials with PLX-PAD by the U.S. Food & Drug Administration (FDA). The Phase I study is designed to evaluate the safety of PLX-PAD in patients with CLI. A total of up to 12 adults with the disease will be included in this dose escalating trial (…)

from http://www.reuters.com/article/pressRelease/idUS125367+10-Sep-2009+BW20090910

Related posts:

• Stem Cell Research Saves Diabetes Patient’s Leg From Amputation
  Amputation & Diabetes — powered by eHow.com
  Victory for Adult Stem Cell Research- Saves a Man’s Leg
  Tom Fisher already had his  right leg amputated due to complications from Diabetes and he was
• Stem Cell Therapeutics Corp. Announces the FDA Has Lifted Its Clinical Hold on the Phase IIb Stroke Trial
  

  Click here to view the embedded video.

  Stem Cell Therapeutics Corp. is pleased to announce the U.S. Food and Drug Administration (FDA) has provided a verbal confirmation to remove its clinical hold placed on NTx®-265 on September

• First Stem Cell Drug Fails 2 Late-Stage Clinical Trials
  What might become the first drug derived from human stem cells failed in two late-stage clinical trials, dealing a setback to the drug’s developer and to the stem cell field
• Geron explains stop on stem cell study
  MENLO PARK, Calif., August 18, 2009 – Geron Corporation announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has
• Video: Stem Cell Research Trial Heals Heart Attack
  Eddie Floyd, a pet store owner had a heart attack a couple of years ago. When he was brought to the hospital, he was asked if he wanted to

If you need more information about STEM CELLS please visit Latest Stem Cells News

This post comes from Latest Stem Cells News
(Digital Fingerprint: 0f6d53ed7d5f01118cf01c21fc9b9d58)